SHIEF Stock Chart & Stats
$0.08
>-$0.01(-3.91%)
At close: 4:00 PM EDT
$0.08
>-$0.01(-3.91%)
Day’s Range― - ―
52-Week Range$0.05 - $0.18
Previous CloseN/A
Volume1.91M
Average Volume (3M)N/A
Market Cap
$71.98M
Enterprise Value$78.73
Total Cash (Recent Filing)$8.39M
Total Debt (Recent Filing)$25.03M
Price to Earnings (P/E)―
Beta-1.82
Next Earnings
Apr 29, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,069,911,300
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)-5.76
Price to Sales (P/S)1.71
P/FCF Ratio-9.83
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$1.03M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthRevenue rose from 25.2M in 2024 to 50.7M in 2025, a 58.2% increase. Sustained top-line expansion can improve operating leverage and broaden the commercial base for Accrufer/Feraccru, although profitability remains to be proven.
Improving Gross MarginGross margin expanded to approximately 44.1% from 42.0%, indicating improving product economics as sales scale. If maintained, this provides greater contribution toward commercial, development and corporate costs and supports a pathway toward eventual profitability.
Debt ReductionEliminating reported debt reduces interest, refinancing and maturity pressure, while the sharp improvement in operating cash burn from 2023 shows progress in financial management. However, the company still needs to reach positive cash generation to gain durable flexibility.
Bears Say
Persistent Net LossesDespite rapid revenue growth and better margins, Shield remained materially loss-making in 2025. Continued net losses limit internally funded investment, indicate that scale has not yet covered the cost base, and leave the timing of sustainable profitability uncertain.
Negative Cash FlowNegative operating and free cash flow show that reported commercial progress has not yet translated into self-funded operations. Ongoing cash consumption can require additional financing, constrain investment in growth and increase dilution or funding risk before breakeven.
Negative EquityNegative equity reflects a fragile capital structure and reduces financial resilience even after debt fell to zero. It can limit access to financing on attractive terms and heighten dilution or refinancing risk while losses and cash deficits continue.
Shield Therapeutics News
SHIEF FAQ
What was Shield Therapeutics PLC’s price range in the past 12 months?
Shield Therapeutics PLC lowest stock price was $0.05 and its highest was $0.18 in the past 12 months.
What is Shield Therapeutics PLC’s market cap?
Shield Therapeutics PLC’s market cap is $71.98M.
When is Shield Therapeutics PLC’s upcoming earnings report date?
Shield Therapeutics PLC’s upcoming earnings report date is Apr 29, 2027 which is in 244 days.
How were Shield Therapeutics PLC’s earnings last quarter?
Shield Therapeutics PLC released its earnings results on Aug 20, 2026. The company reported $0 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Shield Therapeutics PLC overvalued?
According to Wall Street analysts Shield Therapeutics PLC’s price is currently Overvalued.
Does Shield Therapeutics PLC pay dividends?
Shield Therapeutics PLC does not currently pay dividends.
What is Shield Therapeutics PLC’s EPS estimate?
Shield Therapeutics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shield Therapeutics PLC have?
Shield Therapeutics PLC has 1,069,911,300 shares outstanding.
What happened to Shield Therapeutics PLC’s price movement after its last earnings report?
Shield Therapeutics PLC reported an EPS of $0 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Shield Therapeutics PLC?
Currently, no hedge funds are holding shares in SHIEF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shield Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
234.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.64%
Trailing 12-Months
Company Description
Shield Therapeutics PLC
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.